Last updated: October 27, 2026
Polyethylene glycol 800, commonly called PEG 800 or macrogol 800, is a mid-molecular-weight, water-soluble polyether used as a pharmaceutical excipient, solubilizer, plasticizer, humectant, binder, and viscosity modifier. Its commercial outlook is tied to pharmaceutical formulation growth, demand for high-purity excipients, ethylene oxide and ethylene glycol costs, and manufacturing qualification requirements.
PEG 800 is a mature, largely commoditized excipient. It has limited standalone public financial disclosure, no independent Orange Book exclusivity, and no meaningful product-level patent barrier for the base polymer. Value is concentrated in pharmaceutical-grade manufacturing, documentation, batch consistency, regulatory support, supply security, and customer qualification.
What is polyethylene glycol 800 used for in pharmaceuticals?
PEG 800 is a liquid or low-melting polyethylene glycol grade with an average molecular weight near 800. Commercial specifications can vary by manufacturer and pharmacopeial standard.
| Attribute |
PEG 800 profile |
| Chemical name |
Polyethylene glycol |
| Common designation |
PEG 800, macrogol 800 |
| CAS number |
25322-68-3 |
| Main function |
Solubilizer, plasticizer, humectant, binder, viscosity modifier |
| Physical form |
Viscous liquid, semisolid, or low-melting material depending on specification |
| Water solubility |
High |
| Pharmaceutical use |
Oral, topical, semi-solid, and selected parenteral formulation applications |
| Key quality concerns |
Molecular-weight distribution, water content, ethylene oxide residues, aldehydes, acidity, peroxide level, elemental impurities |
| Regulatory status |
Excipient, not an active pharmaceutical ingredient |
| Orange Book status |
No independent listing as a drug product or active ingredient |
PEG 800 can improve the solubility and processability of poorly water-soluble compounds. In topical and semi-solid formulations, it can modify texture and moisture retention. In solid-dose manufacturing, lower-molecular-weight PEG grades can act as binders, plasticizers, or coating components.
The exact suitability depends on the route of administration, concentration, impurity profile, and applicable monograph. Pharmaceutical companies normally qualify a specific supplier and grade rather than purchasing PEG solely by nominal molecular weight.
How large is the PEG 800 pharmaceutical excipient market?
No reliable public source reports PEG 800 as a standalone market category. Market research reports generally combine PEG grades across molecular weights or group PEG with broader excipients, polyethers, solvents, or specialty chemicals.
The addressable market is therefore best analyzed through demand segments:
- Pharmaceutical formulations using PEG as a functional excipient.
- Personal-care and cosmetic products.
- Industrial, lubricant, and polymer applications.
- Laboratory and specialty chemical uses.
Pharmaceutical demand is strategically important but is unlikely to represent the majority of total PEG volume. Industrial and personal-care markets generally consume larger volumes, while pharmaceutical applications command higher prices because of documentation, testing, qualification, and supply requirements.
Market value drivers
| Driver |
Effect on PEG 800 economics |
| Pharmaceutical outsourcing |
Expands demand through contract development and manufacturing organizations |
| Poorly soluble drug pipelines |
Supports use as a solubilizer and formulation aid |
| Topical and semi-solid products |
Supports demand for plasticizing and moisture-control functions |
| Generic-drug manufacturing |
Creates recurring volume demand but increases price pressure |
| High-purity excipient requirements |
Raises margins for qualified pharmaceutical grades |
| Supplier qualification |
Increases switching costs and supports incumbent suppliers |
| Ethylene oxide costs |
Directly affect production economics |
| Energy and freight |
Affect regional pricing and working capital |
| Regulatory documentation |
Raises costs but differentiates pharmaceutical-grade suppliers |
Which companies manufacture pharmaceutical-grade PEG 800?
The principal competitive set includes multinational chemical manufacturers and specialized excipient suppliers. Product naming and molecular-weight ranges differ by company, so a supplier may sell an equivalent PEG grade without using the exact "PEG 800" label.
Relevant supplier groups include:
- BASF, including pharmaceutical excipient PEG and Kollisolv-related product lines.
- Clariant, which markets pharmaceutical excipients and specialty ingredients.
- Croda, including pharmaceutical-grade excipient and formulation materials.
- NOF Corporation, with pharmaceutical and specialty PEG-related products.
- Dow and other large polyether producers serving pharmaceutical and industrial markets.
- Regional producers in China, India, Europe, and the United States.
- Distributors and excipient specialists that provide repackaging, documentation, and regional inventory.
Supplier selection is based on more than molecular weight. Buyers typically assess current good manufacturing practice systems, Drug Master File support, United States Pharmacopeia and European Pharmacopoeia compliance, change-control procedures, audit history, residual impurity controls, and supply continuity.
How does PEG 800 compare with PEG 400 and PEG 3350?
PEG 800 occupies an intermediate position between low-molecular-weight liquid PEG grades and high-molecular-weight solid grades.
| Characteristic |
PEG 400 |
PEG 800 |
PEG 3350 |
| Relative molecular weight |
Lower |
Intermediate |
High |
| Physical character |
Mobile liquid |
Viscous liquid or semisolid |
Wax, solid, or powder |
| Common use |
Solvent, plasticizer, humectant |
Solubilizer, binder, plasticizer, viscosity modifier |
Osmotic agent, laxative, solid-dose excipient |
| Formulation impact |
Lower viscosity and greater mobility |
Balanced viscosity and plasticization |
High viscosity and strong solid-state effects |
| Switching difficulty |
Moderate |
Moderate to high after qualification |
High where dosage form performance depends on polymer size |
| Public market visibility |
High |
Lower |
High because of finished drug products |
PEG 400 generally has broader use as a liquid solvent and plasticizer. PEG 3350 has greater visibility in oral laxative products and high-molecular-weight polymer applications. PEG 800 is less visible commercially but can provide a useful balance between flow, viscosity, water binding, and film-forming properties.
Blending PEG grades is possible in some formulations, but a substitution can alter dissolution, viscosity, drying behavior, content uniformity, preservative performance, and stability. A nominally similar PEG grade is not automatically interchangeable.
What patents protect PEG 800 formulations?
The base PEG polymer is a mature chemical with no practical, broad composition-of-matter exclusivity for ordinary pharmaceutical PEG 800. Patent risk normally arises from the formulation, manufacturing process, delivery system, or combination with an active ingredient.
Formulation patents
Potentially relevant claims can cover:
- Specific PEG molecular-weight ranges.
- Ratios of PEG 400, PEG 800, PEG 3350, or other excipients.
- Solubilized drug compositions.
- Modified-release matrices.
- Topical gels, creams, and ointments.
- PEG-based coatings and films.
- Stability systems that limit oxidation or hydrolysis.
- Drug-loaded nanoparticles or polymeric delivery systems.
- PEG-containing biologic or nucleic-acid delivery systems.
A formulation patent that names PEG 800 may still be narrow if the claims require a particular active ingredient, concentration, dosage form, particle size, release profile, or manufacturing step.
Manufacturing and process patents
Process protection may cover:
- Ethoxylation conditions.
- Molecular-weight distribution control.
- Removal of low-molecular-weight fractions.
- Reduction of aldehydes, peroxides, or residual ethylene oxide.
- Purification and drying methods.
- Production of narrow-distribution PEG materials.
These rights usually protect a producer's manufacturing method rather than the generic use of PEG 800 as an excipient.
When does PEG 800 lose exclusivity?
PEG 800 does not have a drug-style exclusivity timeline. It is a mature excipient rather than a new active pharmaceutical ingredient.
| Exclusivity category |
PEG 800 status |
| New chemical entity exclusivity |
Not applicable |
| Orphan-drug exclusivity |
Not applicable to the excipient itself |
| Pediatric exclusivity |
Not applicable |
| Patent term for base polymer |
No practical active composition patent |
| Orange Book exclusivity |
None for the excipient |
| Formulation patent term |
Depends on the patented drug product or delivery system |
| Process patent term |
Depends on the specific manufacturing claim and jurisdiction |
A finished pharmaceutical product containing PEG 800 can retain patent or regulatory exclusivity even though PEG 800 itself is unprotected. The relevant rights belong to the finished product, active ingredient, formulation, method of use, or delivery technology.
What is the FDA regulatory status of PEG 800?
PEG 800 is regulated as an excipient when used in a drug product. It is not approved as a standalone active drug for purposes of the United States Food and Drug Administration's drug-approval system.
The key regulatory controls are:
- Compliance with applicable USP-NF requirements.
- Use consistent with the approved drug product formulation.
- Supplier qualification and audit controls.
- Testing for identity, purity, water, residual ethylene oxide, ethylene glycol, diethylene glycol, aldehydes, peroxides, and elemental impurities where applicable.
- Assessment of route-specific safety.
- Control of extractables, leachables, and degradation products.
- Change notification under the supplier's quality agreement.
The FDA Inactive Ingredient Database can provide evidence that PEG-related excipients have been used in approved drug products. An IID entry does not automatically establish that every PEG 800 grade is acceptable for every route, dose, or formulation. The regulatory assessment remains product-specific.[1]
Is PEG 800 listed in the Orange Book?
The Orange Book lists approved drug products, active ingredients, patent information, and exclusivity information. It does not create an independent Orange Book listing for PEG 800 as an excipient.
If a PEG 800-containing product is challenged under Paragraph IV, the challenge would target patents listed for the finished drug product. The excipient would be relevant only if the challenged claims require its use or if the ANDA formulation raises infringement or equivalence issues.
Are there Paragraph IV challenges involving PEG 800?
There are no standard Paragraph IV challenges directed solely to PEG 800 as an excipient. Paragraph IV litigation concerns patents listed for an approved drug product under the Hatch-Waxman framework.
PEG 800 can become relevant in three situations:
- A generic applicant uses a formulation that falls within a listed formulation patent.
- The branded product has a delivery-system patent covering a PEG-containing dosage form.
- A supplier or generic applicant relies on a PEG-related process or composition patent that is still enforceable.
For most conventional PEG 800 uses, generic-entry risk comes from the active drug and finished formulation rather than from the excipient itself.
What generic and biosimilar risks affect PEG 800 demand?
Generic-drug growth is a volume positive and a price negative. Generics require qualified excipients, but their manufacturing economics are more sensitive to input costs. Buyers may pressure suppliers for lower pricing, dual-source qualification, and regional inventory.
Biosimilar manufacturing creates a different opportunity. PEG chemistry can be relevant to:
- PEGylated proteins.
- Long-acting biologics.
- PEG-lipid or polymeric delivery systems.
- Nanoparticle and nucleic-acid formulations.
However, conventional PEG 800 is not equivalent to the specialized PEG reagents used in many PEGylation technologies. Those products may require defined chain length, terminal functional groups, narrow dispersity, and pharmaceutical-grade reactive chemistry. PEG 800 demand should not be conflated with the higher-value PEGylation market.
What is the financial trajectory for PEG 800?
The financial trajectory is likely to be stable in volume and modest in price growth, with periodic cost-driven volatility. PEG 800 is unlikely to produce drug-like margins unless sold as a validated pharmaceutical grade with strong documentation and supply assurance.
Revenue and margin profile
| Financial factor |
Expected effect |
| Base polymer demand |
Stable to moderate growth |
| Pharmaceutical-grade premium |
Supports gross margin |
| Generic-drug exposure |
Limits pricing power |
| Raw-material inflation |
Creates periodic price increases |
| Supplier qualification |
Supports retention and repeat orders |
| Multi-source procurement |
Limits long-term pricing power |
| Specialty documentation |
Improves margin versus industrial PEG |
| Regional manufacturing |
Reduces freight exposure but may increase fixed costs |
| Inventory requirements |
Raises working-capital needs |
| Quality failures |
Can create disproportionate recall and remediation costs |
Public companies generally do not report PEG 800 revenue separately. Investors must infer performance from broader excipient, pharmaceutical ingredients, specialty chemicals, or performance materials segments.
The strongest financial position belongs to suppliers that combine high-purity production with regulatory support and customer qualification. Commodity producers compete more directly on price and capacity. Distributors can earn margins through inventory, technical support, regional availability, and documentation management, but they remain exposed to supplier concentration.
What manufacturing and intellectual-property barriers affect PEG 800?
The main barriers are operational and regulatory rather than patent-based.
Manufacturing barriers
- Consistent molecular-weight distribution.
- Low residual ethylene oxide and glycol impurities.
- Control of aldehydes and peroxides.
- Stable color and odor profile.
- Validated cleaning and contamination controls.
- Batch-to-batch reproducibility.
- Traceability of raw materials.
- Compliance with pharmaceutical quality systems.
Intellectual-property barriers
- Proprietary purification and finishing processes.
- Narrow-distribution PEG manufacturing.
- Formulation patents that specify PEG grades.
- Drug-device and delivery-system claims.
- Trade secrets covering process conditions and impurity control.
- Supplier-specific analytical methods.
These barriers increase qualification time and switching costs but do not prevent alternative manufacturers from producing conventional PEG 800.
What licensing deals and commercial partnerships affect PEG 800?
PEG 800 is generally sold through supply agreements, quality agreements, distribution arrangements, and approved-vendor programs rather than headline licensing transactions.
Commercial terms may include:
- Minimum annual purchase volumes.
- Reserved production capacity.
- Regional exclusivity.
- Change-control notification periods.
- Audit rights.
- Pharmacopoeial compliance.
- Dual-source or contingency inventory.
- Price-adjustment mechanisms tied to feedstocks and energy.
Specific PEG 800 licensing revenue is not publicly disclosed as a separate category. Strategic value is more likely to appear in long-term supply relationships with pharmaceutical manufacturers and contract development and manufacturing organizations.
What generic launch scenarios exist for PEG 800-containing products?
PEG 800 creates limited standalone launch risk. The relevant scenarios are:
| Scenario |
Commercial consequence |
| Supplier remains qualified |
No material regulatory impact |
| Supplier changes manufacturing site |
Comparability and regulatory review may be required |
| PEG grade becomes unavailable |
Reformulation or alternate-source qualification |
| Generic uses a different PEG grade |
Equivalence, stability, and performance must be demonstrated |
| Formulation patent covers PEG range |
Potential Paragraph IV litigation |
| Drug product patent expires |
PEG demand may increase through generic entry |
| Excipient price rises |
Margin pressure for generic manufacturers |
| Regulatory impurity concern emerges |
Testing, remediation, or supplier replacement |
Key Takeaways
- PEG 800 is a mature pharmaceutical excipient with broad functional utility and limited standalone patent protection.
- Its market is not reliably reported as a separate financial category.
- Pharmaceutical-grade value comes from purity, documentation, consistency, qualification, and supply continuity.
- The main economic drivers are ethylene oxide costs, energy, freight, pharmaceutical demand, and supplier qualification.
- PEG 800 has no independent Orange Book exclusivity and is not subject to drug-style Paragraph IV challenges.
- Patent risk generally belongs to the finished drug formulation, delivery system, manufacturing process, or method of use.
- Generic-drug growth supports volume but limits pricing power.
- Conventional PEG 800 should be distinguished from specialized PEGylation reagents used in biologics and nucleic-acid delivery.
- The most defensible supplier position combines validated pharmaceutical manufacturing with global inventory and regulatory support.
FAQs
Is PEG 800 the same as PEG 3350?
No. PEG 800 has a much lower average molecular weight and different physical, viscosity, dissolution, and formulation properties. They are not automatically interchangeable.
Is PEG 800 safe as a pharmaceutical excipient?
Safety depends on the formulation, route, dose, impurity profile, and regulatory context. A pharmaceutical-grade material must meet applicable quality requirements and be justified in the finished product.
Does PEG 800 require an FDA Drug Master File?
A Drug Master File can support confidential manufacturing information, but the specific regulatory strategy depends on the supplier, customer, product, and FDA submission. A DMF is not equivalent to FDA approval of the excipient as an active drug.
Can pharmaceutical companies switch PEG 800 suppliers without a new approval?
Not automatically. A supplier change can require comparability work, updated quality documentation, stability data, process assessment, and regulatory notification or approval depending on the product and jurisdiction.
Is PEG 800 exposed to the same concerns as PEG in biologic medicines?
Not necessarily. Conventional PEG 800 is a bulk excipient. PEG used for biologic conjugation or advanced delivery systems may have defined molecular weight, dispersity, functional groups, and impurity controls that are substantially different.
References
-
U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugsatfda
-
United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Polyethylene glycol monograph. U.S. Pharmacopeial Convention.
-
European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Macrogols monograph. Council of Europe.
-
U.S. Food and Drug Administration. (2019). Q3C(R8): Impurities guideline for residual solvents. International Council for Harmonisation.
-
U.S. Food and Drug Administration. (2015). Q3D elemental impurities. International Council for Harmonisation.
